|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 45/06 | |
| A61P 35/00 |
| (11) | Patento numeris | 3206491 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 15851308.5 |
| Europos patento paraiškos padavimo data | 2015-10-16 | |
| (97) | Europos patento paraiškos paskelbimo data | 2017-08-23 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-11-27 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2015/056060 |
| Data | 2015-10-16 |
| (87) | Numeris | WO 2016/061531 |
| Data | 2016-04-21 |
| (30) | Numeris | Data | Šalis |
| 201462065550 P | 2014-10-17 | US | |
| 201562140876 P | 2015-03-31 | US | |
| 201562222746 P | 2015-09-23 | US |
| (72) |
MOSS, Jonathan, US
JOHNSON, Lorin K., US
|
| (73) |
Salix Pharmaceuticals, Inc.,
400 Somerset Corporate Boulevard, Bridgewater, NJ 08807,
US
The University of Chicago, 5801 South Ellis Avenue, Chicago, IL 60637, US |
| (54) | USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION |
| USE OF METHYLNALTREXONE TO ATTENUATE TUMOR PROGRESSION |